Hugh Rienhoff, Imago

Blood can­cer play­er Ima­go Bio­sciences caps off an $80M Se­ries C with an IPO promise for 2021

A lit­tle less than two years af­ter se­cur­ing $40 mil­lion in a Se­ries B, Ima­go Bio­sciences has re­turned to the ven­ture cap­i­tal well with an even big­ger prize.

The San Fran­cis­co-based biotech has pulled in $80 mil­lion for their Se­ries C on Thurs­day, aim­ing to use the funds for one Phase III tri­al for their lead blood can­cer pro­gram, bomedem­stat. The ex­per­i­men­tal drug is be­ing eval­u­at­ed in two Phase IIb stud­ies, in myelofi­bro­sis and es­sen­tial throm­bo­cythemia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.